Hypertension Clinical Trial
— CRUCIALOfficial title:
A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice
NCT number | NCT00407537 |
Other study ID # | A3841047 |
Secondary ID | |
Status | Completed |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | March 2007 |
Est. completion date | October 2009 |
Verified date | January 2021 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.
Status | Completed |
Enrollment | 1531 |
Est. completion date | October 2009 |
Est. primary completion date | October 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 35 Years to 79 Years |
Eligibility | Inclusion Criteria: - Hypertension with three additional risks factors (for example: smoking, type 2 diabetes, family history of early heart disease, history of stroke, age over 55 (men) and 65 (women) Exclusion Criteria: - Subjects currently receiving a statin or stopped statin within 6 months prior to enrollment. - Subjects with a history of myocardial infarction and subjects with coronary bypass graft or intra-coronary interventions. |
Country | Name | City | State |
---|---|---|---|
Costa Rica | Pfizer Investigational Site | Desamparados | San Jose |
Costa Rica | Pfizer Investigational Site | Heredia | |
Costa Rica | Pfizer Investigational Site | San Jose | |
Croatia | Pfizer Investigational Site | Breznicki Hum | |
Croatia | Pfizer Investigational Site | Cakovec | |
Croatia | Pfizer Investigational Site | Crikvenica | |
Croatia | Pfizer Investigational Site | Karlovac | |
Croatia | Pfizer Investigational Site | Rijeka | |
Croatia | Pfizer Investigational Site | Spisic Bukovica | |
Croatia | Pfizer Investigational Site | Split | |
Croatia | Pfizer Investigational Site | Sv. Kriz Zacretje | |
Croatia | Pfizer Investigational Site | Varazdin | |
Croatia | Pfizer Investigational Site | Zagreb | |
Czechia | Pfizer Investigational Site | Brno | |
Czechia | Pfizer Investigational Site | Klatovy | |
Czechia | Pfizer Investigational Site | Kralupy nad Vltavou | |
Czechia | Pfizer Investigational Site | Lanskroun | |
Czechia | Pfizer Investigational Site | Olomouc | |
Czechia | Pfizer Investigational Site | Pelhrimov | |
Czechia | Pfizer Investigational Site | Praha 4 | |
Czechia | Pfizer Investigational Site | Praha 8 | |
Czechia | Pfizer Investigational Site | Pruhonice | |
Czechia | Pfizer Investigational Site | Usti nad Labem | |
Czechia | Pfizer Investigational Site | Vratimov | |
Czechia | Pfizer Investigational Site | Zlin 4 | |
Dominican Republic | Pfizer Investigational Site | San Cristobal | |
Dominican Republic | Pfizer Investigational Site | Santo Domingo | |
Dominican Republic | Pfizer Investigational Site | Santo Domingo | |
Indonesia | Pfizer Investigational Site | Bandung | |
Indonesia | Pfizer Investigational Site | Cilandak | Jakarta Selatan |
Indonesia | Pfizer Investigational Site | Jakarta | |
Indonesia | Pfizer Investigational Site | Jakarta | |
Indonesia | Pfizer Investigational Site | Semarang | |
Indonesia | Pfizer Investigational Site | Surabaya | |
Indonesia | Pfizer Investigational Site | Tangerang | |
Indonesia | Pfizer Investigational Site | Tanggerang | |
Jordan | Pfizer Investigational Site | Amman | |
Jordan | Pfizer Investigational Site | Amman | |
Jordan | Pfizer Investigational Site | Irbid | |
Korea, Republic of | Pfizer Investigational Site | Busan | |
Korea, Republic of | Pfizer Investigational Site | Busan | |
Korea, Republic of | Pfizer Investigational Site | Daegu | |
Korea, Republic of | Pfizer Investigational Site | Daegu | |
Korea, Republic of | Pfizer Investigational Site | Daejeon | |
Korea, Republic of | Pfizer Investigational Site | Gwangju | |
Korea, Republic of | Pfizer Investigational Site | Incheon | |
Korea, Republic of | Pfizer Investigational Site | Seongnam-si | Gyeonggi-do |
Korea, Republic of | Pfizer Investigational Site | Seoul | |
Korea, Republic of | Pfizer Investigational Site | Seoul | |
Korea, Republic of | Pfizer Investigational Site | Seoul | |
Korea, Republic of | Pfizer Investigational Site | Seoul | |
Korea, Republic of | Pfizer Investigational Site | Seoul | |
Korea, Republic of | Pfizer Investigational Site | Seoul | |
Korea, Republic of | Pfizer Investigational Site | Seoul | |
Korea, Republic of | Pfizer Investigational Site | Seoul | |
Korea, Republic of | Pfizer Investigational Site | Seoul, | |
Korea, Republic of | Pfizer Investigational Site | Suwon | |
Korea, Republic of | Pfizer Investigational Site | Wonju-si | Gangwon-Do |
Kuwait | Pfizer Investigational Site | Kuwait | |
Kuwait | Pfizer Investigational Site | Sasat | |
Lebanon | Pfizer Investigational Site | Beirut | |
Lebanon | Pfizer Investigational Site | Jbeil | |
Malaysia | Pfizer Investigational Site | Batu Caves | Selangor |
Malaysia | Pfizer Investigational Site | Butterworth | |
Malaysia | Pfizer Investigational Site | Kuala Lumpur | |
Malaysia | Pfizer Investigational Site | Kuala Lumpur | |
Malaysia | Pfizer Investigational Site | Kuala Pilah | Negeri Sembilan |
Malaysia | Pfizer Investigational Site | Petaling Jaya | Selangor |
Malaysia | Pfizer Investigational Site | Seremban | Negeri Sembilan |
Mexico | Pfizer Investigational Site | Durango | |
Mexico | Pfizer Investigational Site | Guadalajara | Jalisco |
Mexico | Pfizer Investigational Site | Guadalajara | Jalisco |
Mexico | Pfizer Investigational Site | Mexico | DF |
Mexico | Pfizer Investigational Site | Mexico | DF |
Mexico | Pfizer Investigational Site | Mexico | DF |
Mexico | Pfizer Investigational Site | Mexico | DF |
Mexico | Pfizer Investigational Site | San Luis Potosi | |
Mexico | Pfizer Investigational Site | Toluca | Estado De Mexico |
Panama | Pfizer Investigational Site | Panama | |
Panama | Pfizer Investigational Site | Panama City | |
Philippines | Pfizer Investigational Site | Makati City | |
Philippines | Pfizer Investigational Site | Manila | |
Philippines | Pfizer Investigational Site | Marikina City | |
Philippines | Pfizer Investigational Site | Quezon City | |
Philippines | Pfizer Investigational Site | San Juan | Metro Manila |
Russian Federation | Pfizer Investigational Site | Moscow | |
Russian Federation | Pfizer Investigational Site | Moscow | |
Russian Federation | Pfizer Investigational Site | Moscow | |
Russian Federation | Pfizer Investigational Site | Moscow | |
Russian Federation | Pfizer Investigational Site | Saint Petersburg | |
Russian Federation | Pfizer Investigational Site | Saint-Petersburg | |
Russian Federation | Pfizer Investigational Site | Saint-Petersburg | |
Russian Federation | Pfizer Investigational Site | Smolensk | |
Russian Federation | Pfizer Investigational Site | St. Petersburg | |
Russian Federation | Pfizer Investigational Site | St. Petersburg | |
Russian Federation | Pfizer Investigational Site | St. Petersburg | |
Russian Federation | Pfizer Investigational Site | Volgograd | |
Russian Federation | Pfizer Investigational Site | Voronezh | |
Saudi Arabia | Pfizer Investigational Site | Riyadh 11426 | |
Taiwan | Pfizer Investigational Site | Kaohsiung | |
Taiwan | Pfizer Investigational Site | Kaohsiung | |
Taiwan | Pfizer Investigational Site | Taichung | |
Taiwan | Pfizer Investigational Site | Taichung | |
Taiwan | Pfizer Investigational Site | Tainan | |
Taiwan | Pfizer Investigational Site | Tainan | |
Taiwan | Pfizer Investigational Site | Taipei | |
Taiwan | Pfizer Investigational Site | Taipei | |
Taiwan | Pfizer Investigational Site | Taipei | |
Thailand | Pfizer Investigational Site | Bangkok | |
Thailand | Pfizer Investigational Site | Rajthevee | Bangkok |
Thailand | Pfizer Investigational Site | Saimai | Bangkok |
Turkey | Pfizer Investigational Site | Ankara | |
Turkey | Pfizer Investigational Site | Ankara | |
Turkey | Pfizer Investigational Site | Istanbul | |
Turkey | Pfizer Investigational Site | Istanbul | |
Turkey | Pfizer Investigational Site | Istanbul | |
Turkey | Pfizer Investigational Site | Istanbul | |
Turkey | Pfizer Investigational Site | Izmir | |
Turkey | Pfizer Investigational Site | Izmir | |
United Arab Emirates | Pfizer Investigational Site | Abu Dhabi | |
United Arab Emirates | Pfizer Investigational Site | Al Ain | |
United Arab Emirates | Pfizer Investigational Site | Dubai | |
Venezuela | Pfizer Investigational Site | Caracas | Dtto Capital/Municipio Libertador |
Venezuela | Pfizer Investigational Site | Caracas | Dtto Capital/Municipio Libertador |
Venezuela | Pfizer Investigational Site | Naguanagua/Valencia | Carabobo |
Venezuela | Pfizer Investigational Site | Valencia | Estado Carabobo |
Lead Sponsor | Collaborator |
---|---|
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
Costa Rica, Croatia, Czechia, Dominican Republic, Indonesia, Jordan, Korea, Republic of, Kuwait, Lebanon, Malaysia, Mexico, Panama, Philippines, Russian Federation, Saudi Arabia, Taiwan, Thailand, Turkey, United Arab Emirates, Venezuela,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Framingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 12 | Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated at the end of study treatment (Month 12). | Baseline, Month 12 | |
Secondary | Framingham 10-year Risk of Total CHD at Month 4 | Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated after 4 months of treatment (Month 4). | Baseline, Month 4 | |
Secondary | European Systematic COronary Risk Evaluation (SCORE) 10-year Risk of Fatal Cardiovascular Disease (CVD) at Month 12 | European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 12 months of study treatment (Month 12). | Baseline, Month 12 | |
Secondary | European SCORE 10-year Risk of Fatal CVD at Month 4 | European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 4 months of study treatment (Month 4). | Baseline, Month 4 | |
Secondary | Framingham 10-year Risk of Stroke at Month 12 | Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific "calibration factor" for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12). | Baseline, Month 12 | |
Secondary | Framingham 10-year Risk of Stroke at Month 4 | Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific "calibration factor" for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12). | Baseline, Month 4 | |
Secondary | Change From Baseline in Framingham 10-year Risk of Developing Total CHD | Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. Change from baseline calculated as mean at observation minus mean at Baseline. | Baseline, Month 4, Month 12 | |
Secondary | Change From Baseline European SCORE 10-year Risk of Developing Fatal CVD | European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. Change from baseline calculated as mean at observation minus mean at Baseline. | Baseline, Month 4, Month 12 | |
Secondary | Mean Systolic and Diastolic Blood Pressure at Month 4 | Month 4 | ||
Secondary | Mean Systolic and Diastolic Blood Pressure at Month 12 | Month 12 | ||
Secondary | Change From Baseline in Systolic Blood Pressure (SBP) at Month 4 | Baseline, Month 4 | ||
Secondary | Change From Baseline in Diastolic Blood Pressure (DBP) at Month 4 | Baseline, Month 4 | ||
Secondary | Change From Baseline in SBP at Month 12 | Baseline, Month 12 | ||
Secondary | Change From Baseline in DBP at Month 12 | Baseline, Month 12 | ||
Secondary | Mean Lipid Parameters at Month 4 | Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. | Month 4 | |
Secondary | Mean Lipid Parameters at Month 12 | Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. | Month 12 | |
Secondary | Change From Baseline in Lipid Parameters at Month 4 | Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. Change from baseline measured as mean at Month 4 minus mean at Baseline. | Baseline, Month 4 | |
Secondary | Change From Baseline in Lipid Parameters at Month 12 | Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. | Baseline, Month 12 | |
Secondary | Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for Blood Pressure at 4 and 12 Months | Goals set at <140/90 mmHg according to the seventh Joint National Committee (JNC) on prevention, detection, evaluation, and treatment of high blood pressure and <140/90 mm Hg or <130/80 mm Hg for diabetics ccording to the European Society of Cardiology (ESC) guidelines. | Month 4, Month 12 | |
Secondary | Percentage of Participants at Conventional Treatment Goals According to Global and Local Guidelines for LDL at 4 and 12 Months | Goal set at <100 mg/dL according to the United States (US) National Cholesterol Education Program Adult Treatment Panel 3 and at <80 mg/dL according to the European (EU) Society of Cardiology guidelines. | Month 4, Month 12 | |
Secondary | Number of Participants With Lipid and Antihypertensive Treatments Used at 4 and 12 Months | Treatments indicative of prescribed medications other than study provided Caduet. | Month 4, Month 12 | |
Secondary | Number of Participants With Increase of Treatment Dosages After 4 Months. | Treatments indicative of prescribed medications other than study provided Caduet. | Month 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |